CRISPR Therapeutics AG
NASDAQ:CRSP
51.88 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 370 | 0.436 | 913.081 | 0.543 | 289.59 | 3.124 | 40.997 | 5.164 | 0.247 | 0 |
| Cost of Revenue
| 130.25 | 110.25 | 17.953 | 269.407 | 179.362 | 113.773 | 69.8 | 42.238 | 12.573 | 1.513 |
| Gross Profit
| 239.75 | -109.814 | 895.128 | -268.864 | 110.228 | -110.649 | -28.803 | -37.074 | -12.326 | -1.513 |
| Gross Profit Ratio
| 0.648 | -251.867 | 0.98 | -495.145 | 0.381 | -35.419 | -0.703 | -7.179 | -49.903 | 0 |
| Reseach & Development Expenses
| 387.332 | 461.645 | 438.633 | 266.946 | 179.362 | 113.773 | 69.8 | 42.238 | 12.573 | 1.513 |
| General & Administrative Expenses
| 76.162 | 102.464 | 102.802 | 88.208 | 63.488 | 48.294 | 35.845 | 31.056 | 13.403 | 5.114 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 76.162 | 102.464 | 102.802 | 88.208 | 63.488 | 48.294 | 35.845 | 31.056 | 13.403 | 5.114 |
| Other Expenses
| 71.816 | -0.762 | -1.882 | -0.176 | 20.566 | -5.485 | -0.197 | 78.512 | 0.016 | -0.236 |
| Operating Expenses
| 462.288 | 563.347 | 539.553 | 354.978 | 242.85 | 162.067 | 105.645 | 73.294 | 25.976 | 6.627 |
| Operating Income
| -222.538 | -673.161 | 373.528 | -354.435 | 46.74 | -158.943 | -64.648 | -68.13 | -25.729 | -6.627 |
| Operating Income Ratio
| -0.601 | -1,543.947 | 0.409 | -652.735 | 0.161 | -50.878 | -1.577 | -13.193 | -104.166 | 0 |
| Total Other Income Expenses Net
| 71.816 | 22.661 | 6.003 | 6.379 | 20.566 | -5.485 | -1.96 | 53.462 | 0.016 | -0.236 |
| Income Before Tax
| -150.722 | -650.5 | 379.531 | -348.056 | 67.306 | -164.428 | -66.608 | -22.718 | -25.821 | -6.863 |
| Income Before Tax Ratio
| -0.407 | -1,491.972 | 0.416 | -640.987 | 0.232 | -52.634 | -1.625 | -4.399 | -104.538 | 0 |
| Income Tax Expense
| 2.888 | -0.325 | 1.87 | 0.809 | 0.448 | 0.553 | 1.749 | 0.484 | 0.007 | -0.063 |
| Net Income
| -153.61 | -650.175 | 377.661 | -348.865 | 66.858 | -164.981 | -68.357 | -23.202 | -25.828 | -6.8 |
| Net Income Ratio
| -0.415 | -1,491.227 | 0.414 | -642.477 | 0.231 | -52.811 | -1.667 | -4.493 | -104.567 | 0 |
| EPS
| -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | -1.89 | -0.88 | -0.23 |
| EPS Diluted
| -1.94 | -8.36 | 4.7 | -5.29 | 1.17 | -3.44 | -1.71 | -1.89 | -0.88 | -0.23 |
| EBITDA
| -202.701 | -673.161 | 373.528 | -345.251 | 46.74 | -158.943 | -61.624 | -25.225 | -25.586 | -6.825 |
| EBITDA Ratio
| -0.548 | -1,543.947 | 0.409 | -635.821 | 0.161 | -50.878 | -1.503 | -4.885 | -103.587 | 0 |